HighTower Advisors LLC Sells 8,497 Shares of Sanofi $SNY

Key Points

• HighTower Advisors LLC reduced its stake in Sanofi by 9.3%, selling 8,497 shares during the first quarter, bringing its total holdings to 82,574 shares valued at approximately $4.58 million.
• Several institutional investors, including Bank of America Corp and Price T Rowe Associates, have increased their positions in Sanofi, leading to a total of 14.04% institutional ownership.
• Sanofi's stock has a consensus rating of Buy with a target price set at $62.00, despite missing earnings expectations for the last quarter.

HighTower Advisors LLC lessened its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 9.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,574 shares of the company's stock after selling 8,497 shares during the period. HighTower Advisors LLC's holdings in Sanofi were worth $4,580,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in shares of Sanofi by 3.8% during the 4th quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock worth $579,587,000 after buying an additional 441,637 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Sanofi by 88.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after buying an additional 5,091,304 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of Sanofi by 58.5% during the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company's stock worth $218,933,000 after buying an additional 1,456,269 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Sanofi by 1.0% during the 4th quarter. Nuveen Asset Management LLC now owns 3,676,224 shares of the company's stock worth $177,304,000 after buying an additional 34,660 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Sanofi by 6.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 3,277,394 shares of the company's stock worth $181,764,000 after buying an additional 211,641 shares during the last quarter. Institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

Sanofi stock traded up $0.74 during trading hours on Friday, hitting $51.35. The company had a trading volume of 1,457,301 shares, compared to its average volume of 2,787,292. The firm has a market cap of $126.09 billion, a PE ratio of 12.49, a PEG ratio of 1.22 and a beta of 0.48. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. Sanofi has a one year low of $44.73 and a one year high of $60.12. The firm has a 50-day moving average of $48.62 and a 200 day moving average of $51.73.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. During the same period in the previous year, the company posted $1.73 EPS. Sanofi's revenue for the quarter was down 7.0% compared to the same quarter last year. On average, sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of recent research reports. Guggenheim restated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Barclays reiterated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Morgan Stanley set a $56.00 target price on shares of Sanofi in a research note on Monday, June 2nd. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Sanofi in a research note on Tuesday, August 5th. Three research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $62.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.